Capitalized and powered for the next leg of growth



BFSI - NBFCs > Result Update > May 5, 2024

With the recent capital raise of Rs13.3bn (Rs2.75bn of CCD and Rs10.58bn of Warrants) and acquisition of embedded lending Fintech ("MyShubhLife"), Ugro Capital is well capitalized and powered for the next leg of growth from Rs90bn to Rs200bn of AUM, with RoA improving to 4.3% from 2.3% over FY24-27E. Strong capital adequacy post the capital raise and visibility on the same in the coming years, as well as seasoning of the loan book, will likely drive better credit rating and lower cost of borrowing. Focus on higher yielding Micro LAP loans along with improved cost of borrowing and continued operating leverage will drive sustained RoA improvement. To reflect the Q4 developments and

capital raise, we adjusted our FY25-26 estimates and introduced FY27E. We reiterate BUY with revised Mar-25E TP of Rs410 (implying FY26E P/B of 1.8x).

UGRO Capital: Finance	cial Snapsho	ot (Standal	one)		
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net profits	398	1,193	1,868	3,367	5,274
AUM growths (%)	104.8	48.8	41.7	34.9	31.0
NII growths (%)	40.7	39.7	52.2	48.9	34.4
NIMs (%)	12.5	14.8	15.9	16.9	17.2
PPOP growth (%)	183.6	109.8	38.2	60.7	47.9
Adj. EPS (Rs)	5.7	13.4	20.4	28.9	37.2
Adj. EPS growth (%)	176.2	135.3	52.3	41.6	28.9
Adj. BV (INR)	142.0	157.0	206.1	230.5	267.7
Adj. BVPS growth (%)	3.6	10.6	31.3	11.8	16.2
RoA (%)	1.1	2.3	2.7	3.7	4.3
RoE (%)	4.1	9.9	10.6	14.3	14.9
P/E (x)	49.7	21.1	13.9	9.8	7.6
P/ABV (x)	2.0	1.8	1.4	1.2	1.1

Source: Company, Emkay Research

FY24 marks a year of solid progress

Ugro Capital continues to deliver strong performance with Q4FY24 PAT at Rs327mn, registering 133% YoY growth (flat QoQ), led by a robust income of ~Rs1.2bn in Q4 (vs Rs764mn in Q3) from its off-book AUM. Overall, NIM+Fees (on book AUM) stood at 16.9% – a significant jump of 209bps QoQ/233bps YoY, on account of increasing off-book AUM and some rate reset to end customer, resulting in higher upfront income recognition. Opex-to-AUM increased marginally to 4.84% vs 4.34% in Q3, which could be due to addition of 46 new branches in the quarter and continued investment in digital infrastructure. Credit cost on total AUM came in at 1.89%, increasing by 40bps/64bps QoQ/YoY, largely on account of higher than normal write-off (Rs100mn higher write-off), while asset quality remains stable with GNPA/NNPA at 2%/1.1%, respectively, with a PCR of 48%.(Exhibit-4)

Capital raise and acquisition to power the company for the next leg of growth

The acquisition of 'MySubhLife' (MSL) is expected to boost the customer acquisition process and market penetration of Ugro. The management expects incremental AUM of Rs15bn over the next 3 years. In terms of profitability, we expect UGRO to start delivering $\sim\!15\%$ ROE from FY27, on account of improving yields and fee income (also supported by MSL acquisition), Opex moderation, and stable credit cost. The recent fund raise of $\sim\!$ Rs13.2bn is a strategic call, where the upfront capital received would be $\sim\!$ Rs5.4bn and the $\sim\!$ Rs7.9bn balance by Nov-25. With this capital raise, the company is well capitalized to grow its AUM to Rs200bn and its on-book AuM to Rs100bn over the next 2-3 years.

We expect strong growth to continue; reiterate BUY

To reflect the Q4 developments, Management's commentary and the capital raise, we have adjusted our FY25-26 estimates, leading to meaningful changes in our headline estimates, and introduce FY27E. We reiterate our BUY rating on the stock with our ERE-based revised Mar-25E TP of Rs410/sh (from Rs430 earlier) as we see Ugro to be better prepared to grow profitably and compete in the MSME lending space. (Exhibit-3)

TARGET PRICE (Rs): 410

Target Price - 12M	Mar-25
Change in TP (%)	(3.5)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	45.1
CMP (03-May-24) (Rs)	282.7

Stock Data	Ticker
52-week High (Rs)	320
52-week Low (Rs)	173
Shares outstanding (mn)	92.8
Market-cap (Rs bn)	26
Market-cap (USD mn)	314
Net-debt, FY25E (Rs mn)	974
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	81.2
ADTV-3M (USD mn)	1.0
Free float (%)	-
Nifty-50	22,476
INR/USD	83.4
Shareholding, Mar-24	
Promoters (%)	2.2
FPIs/MFs (%)	19.8/3.8

Price Performance											
(%)	1M	ЗМ	12M								
Absolute	13.9	3.7	47.9								
Rel. to Nifty	13.6	0.9	19.0								

1-Year share price trend (Rs)



Avinash Singh

avinash.singh@emkayglobal.com +91 22 6612 1327

Kishan Rungta

kishan.rungta@emkayglobal.com +91 22 6624 2490

Mahek Shah

mahek.shah@emkayglobal.com +91 22 6612 1218

Exhibit 1: UGRO Acquires MSL (DTPL) through a combination of 64:36 equity cash transaction

Transact	ion details	What MSL offers	Expected outcome
Ugro Capital Networth (FY24) – Rs14.38bn	, , ,	MSL is an embedded finance fintech platform, partnered with Pine Labs, Fino, Airtel Payments Bank, MobiKwik, Spice Money etc.	Large addressable market — embedded finance for small retailers market is valued at Rs1.1trn
	Revenue (SA) in FY23 was ~Rs101mn	Inartners like Pine Lan Fino Airtel Payments Bank	Increase geographic presence and improved cross-sell and fee income
P/BV - 1.8x	P/BV - 1.9x	It uses cutting-edge tech stack and leveraged data to provide tailored offerings like daily and weekly installment options along with overdraft facility	Improved yields, which has been Ugro's focus area
Mcap - Rs26.2bn	Enterprise value of Rs450mn		Ugro expects to add an incremental ~200k customers over the next 3 years
UGRO acquires MSL of 64:36 equity cash tranches	through a combination transaction in 2		Ugro anticipates an incremental AUM of Rs15bn, PAT of Rs1bn with MSL as its subsidiary in the next 3 years
Tranche 1 – Rs280r shareholding in DTPI	• •		
Tranche 2 – Rs170r shareholding in DTPI			

Source: Company, Emkay Research; Note: #Datasigns Technologies Private Limited ("DTPL")

Acquisition to enhance asset and profitability growth

Post completion of acquisition of 'MYSHUBHLIFE' (MSL) — a prominent Embedded Finance Fintech platform — Ugro expects to onboard over 200k retailers (majorly small shopkeepers and distributors), offering them customized product/services according to their needs, like daily and weekly installment options with overdraft facility in the next three years. This strategy is expected to provide a good cross-sell and up-sell opportunity for its existing products, thus increasing its reach and products per customer, resulting in incremental AUM/PAT of Rs15bn/1bn, respectively.

Exhibit 2: Movement in networth due to fund raise

	FY24	FY25E	FY26E
Existing share o/s (mn)	91.6		
Issuance of CDD @264/CCD	-		10.3
Warrants issued @264/CCD (mn)			39.8
Total Share o/s (mn)	91.6	91.6	141.7
Receipt of CCD		2,714	
Receipt of Warrant		2,628	7,884
Networth (Rs mn)	14,384	18,879	32,656

Source: Company, Emkay Research; Note: assuming full conversion of warrant and CCD in 18 months (Nov-25)

Capital raise to provide uninterrupted growth path

Ugro's Board has approved raising Rs13.23bn by the issuance of 10.4mn CCDs (Rs2.75bn) and 40.07bn Warrants (Rs10.58bn) at Rs264 each, both convertible to Ugro equity shares at any time during the 18 months following the issuance date. The proceeds are expected to come in 2 parts for the company — a total sum of Rs5.3bn (which will form part of Tier-1 capital immediately post-issuance) in FY25, and Rs7.9bn as capital over the next 18 months. These funds should support Ugro's sturdy growth plans for the coming 2 years, and make a case for its ratings upgrade. The capital infusion garnered significant support from Samena Capital, an existing private equity investor, pledging Rs5bn via Warrants, along with prominent investors and family offices, thus demonstrating their confidence in the company.

Call KTA:

- Management informed that its focus is more toward improving profitability, while growing its AUM at 30% CAGR in a strategically risk-calibrated manner for the next 2 years.
- ROA to reach at ~4% levels by FY26.
- Cost-to-income should continue to improve on a quarterly basis and sustain at 40-45% over the next 8 quarters. While the overall credit cost is likely to sustain at 2% levels, thus improving profitability.
- Margins likely to improve on account of increasing share of fee income, yield improvement to be led by improving product mix, and cost moderation on account of diverse source of funding and rating improvement.
- The On-Book: Off-Book mix is expected to reach 50:50 mix, with increasing share of highyield products.
- Currently operating from 150 branches and will add another 100 in FY25; taking the total to 250 branches.
- Acquisition of embedded finance company "MSL" will improve reach and cross-sell opportunity, thus improving margins and fee income.
- Intense competition in some segments led to balance transfer (out), thus impacting AUM growth marginally in Q4.

Exhibit 3: Valuation matrix

	CMP/TP	Upside	Mkt Cap			P/E (x)		RoA (%)		RoE (%)		Book Value (Rs/sh)		EPS (Rs)							
	(Rs/sh) · (Rs bh)	(Rs bn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	
At current market price	283	45%	26.2	1.37	1.23	1.06	13.87	9.80	7.62	2.3	2.7	3.7	10.6	14.3	14.9	206	230	268	20	29	37
At target price	410		26.2	1.99	1.78	1.53	20.11	14.20	11.04	2.3	2.7	3.7	10.6	14.3	14.9	206	230	268	20	29	37

Source: Company, Emkay Research

Exhibit 4: Q4FY24 result snapshot

UGRO result snapshot (Rs mn)	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	QoQ change	YoY Change
NII	507	688	665	661	636	-4%	25%
NIMs (%)	5.8	7.4	6.6	6.0	5.3	-71bps	-51bps
NII + Fees	1,268	1,257	1,482	1,626	2,022	24%	60%
NIMs + Fees (%)	14.6	13.4	14.8	14.8	16.9	209bps	233bps
Cost of Borrowing (%)	11.98	11.42	11.81	11.71	12.09	38bps	11bps
Opex-to-AUM (%)	5.07	4.30	4.61	4.34	4.84	50bps	-24bps
PPoP	511	566	654	761	970	27%	90%
Credit cost on AUM (%)	1.25	1.30	1.37	1.49	1.89	40bps	64bps
Credit cost on on-book AUM (%)	2.0	2.2	2.4	2.7	3.5	75bps	145bps
PAT	140	252	289	325	327	1%	133%
Networth	9,840	13,373	13,710	14,049	14,384	2%	46%
AUM	60,810	67,770	75,920	83,640	90,470	8%	49%
Disbursement	14,590	12,790	14,770	15,520	15,540	0%	7%
GS3 (%) - Reported	2.46	2.67	2.85	3.15	3.09	-6bps	63bps
NS3 (%) - Reported	1.31	1.45	1.52	1.67	1.64	-3bps	33bps
GNPA % (GS3 on Total AUM)	1.60	1.80	1.92	2.04	2.02	-2bps	42bps
NNPA % (NS3 on Total AUM)	0.90	1.00	1.00	1.06	1.07	1bps	17bps
ROA - Reported	2.20	2.20	2.30	2.40	2.20	-20bps	0bps
ROE - Reported	9.50	8.70	8.50	9.40	9.20	-20bps	-30bps
PCR (%)	48.6	48.0	49.0	49.0	48.0	-100bps	-60bps

Exhibit 5: AUM trend

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
AUM (Rs bn)	25.89	29.69	36.57	43.75	50.96	60.81	67.77	75.92	83.64	90.47
QoQ growth	34%	15%	23%	20%	16%	19%	11%	12%	10%	8%

Source: Company, Emkay Research

Exhibit 6: AUM mix - On-Balance sheet: Off-Balance sheet

AUM Mix (Rs mn)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
On Book	24,077.7	24,910	28,750	31,030	33,210	36,390	38,480	41,756	46,002	49,690
Off Book	1,812.3	4,780	7,820	12,720	17,750	24,420	29,290	34,164	37,638	40,780
Total AUM	25,890	29,690	36,570	43,750	50,960	60,810	67,770	75,920	83,640	90,470
On Book	93%	84%	79%	71%	65%	60%	57%	55%	55%	55%
Off Book	7%	16%	21%	29%	35%	40%	43%	45%	45%	45%

Source: Company, Emkay Research

Exhibit 7: AUM mix - segmental

Product Mix	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Prime - Secured Loans	31.4%	29.6%	28.7%	28.4%	29.3%	28.5%	26.9%	26.4%
Prime - Unsecured Loans	27.3%	28.8%	30.0%	31.2%	31.1%	31.3%	31.9%	32.5%
Micro Enterprise Loan	4.6%	5.5%	6.6%	7.8%	8.1%	8.4%	8.6%	9.0%
Supply Chain Financing	9.7%	9.1%	9.0%	9.3%	8.6%	8.8%	8.6%	7.0%
Machinery Loan	9.9%	10.6%	11.1%	11.5%	11.8%	11.8%	12.4%	12.9%
Partnerships & Alliances	17.0%	16.4%	14.6%	11.8%	11.1%	11.2%	11.6%	12.3%

Source: Company, Emkay Research

Exhibit 8: Disbursement trend

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Net Disbursement (Rs bn)	8.17	6.12	9.16	11.01	11.64	14.59	12.79	14.77	15.52	15.54
QoQ growth	27%	-25%	50%	20%	6%	25%	-12%	15%	5%	0%


Source: Company, Emkay Research

Exhibit 9: Product-wise disbursement mix

Disbursement Mix	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Prime - Secured Loans	21.0%	22.8%	25.3%	24.7%	28.4%	20.6%	15.7%	17.0%
Prime - Unsecured Loans	33.3%	32.1%	33.2%	28.6%	33.5%	35.5%	38.0%	40.3%
Micro Enterprise Loan	9.9%	10.9%	11.7%	14.1%	11.8%	12.7%	11.6%	13.1%
Supply Chain Financing	55.5%	55.4%	66.6%	66.0%	59.3%	75.5%	84.4%	84.3%
Machinery Loan	7.2%	5.3%	5.6%	7.5%	0.9%	5.8%	3.4%	-5.7%
Partnerships & Alliances	13.0%	11.4%	11.5%	11.9%	12.0%	11.3%	14.5%	14.6%


Result in charts

Exhibit 10: Strong growth despite intense competition in some seaments




Source: Company, Emkay Research

Exhibit 11: Increasing share of Off-book AUM; target is to reach **50**%




Source: Company, Emkay Research

Exhibit 12: Disbursement growth impacted by weakness in supply chain financing




Source: Company, Emkay Research

Exhibit 13: CoFs is expected to moderate over the medium- to longer-term



Source: Company, Emkay Research

Exhibit 14: Increasing share of off-book income leading to improved margins



Source: Company, Emkay Research

Exhibit 15: Improving cost-to-income on a quarterly basis






Exhibit 16: Overall credit cost remained at comfortable levels




Source: Company, Emkay Research

Exhibit 17: GS3 & NS3 trends




Source: Company, Emkay Research

Exhibit 18: GNPA & NNPA trends



Source: Company, Emkay Research


Exhibit 19: ROA & ROE are expected to improve in coming quarters



Source: Company, Emkay Research

Story in charts

Exhibit 20: We expect AUM to grow at 36% CAGR over FY24-27E



Source: Company, Emkay Research

Exhibit 21: Strong disbursement growth led by increasing branches






Exhibit 22: CoFs to moderate due to diverse source of funding and rating improvement




Source: Company, Emkay Research

Exhibit 23: Margin improvement led by improving asset mix




Source: Company, Emkay Research

Exhibit 24: Operating expenses to moderate as business scales




Source: Company, Emkay Research

Exhibit 25: Credit cost on AUM to sustain below the 2% level




Source: Company, Emkay Research

Exhibit 26: Stable asset quality



Source: Company, Emkay Research

Exhibit 27: Improved profitability; cost moderation and stable asset quality leading to improved ROA & ROE



Source: Company, Emkay Research; Note: #FY25-26E ROE adjusted for fund raise - conversion of warrant and CCD expected in Nov-26

UGRO Capital: Standalone Financials and Valuations

V/E M	E140E	E140.6	=\/>==	=1/2.5=	=><==
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	4,829	7,079	9,642	12,872	17,228
Interest Expense	2,933	4,429	5,608	6,867	9,155
Net interest income	1,896	2,650	4,034	6,005	8,073
NII growth (%)	40.7	39.7	52.2	48.9	34.4
Non interest income	1,944	3,737	5,018	6,744	9,132
Total income	3,841	6,387	9,053	12,749	17,205
Operating expenses	2,435	3,437	4,976	6,198	7,517
PPOP	1,406	2,950	4,076	6,552	9,689
PPOP growth (%)	183.6	109.8	38.2	60.7	47.9
Provisions & contingencies	568	1,163	1,563	2,019	2,590
PBT	838	1,788	2,513	4,532	7,098
Extraordinary items	0	0	0	0	C
Tax expense	441	594	646	1,165	1,824
Minority interest	0	0	0	0	C
Income from JV/Associates	0	0	0	0	C
Reported PAT	398	1,193	1,868	3,367	5,274
PAT growth (%)	173.4	200.0	56.5	80.3	56.6
Adjusted PAT	398	1,193	1,868	3,367	5,274
Diluted EPS (Rs)	5.7	13.4	20.4	28.9	37.2
Diluted EPS growth (%)	176.2	135.3	52.3	41.6	28.9
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
Effective tax rate (%)	52.6	33.2	25.7	25.7	25.7
Net interest margins (%)	12.5	14.8	15.9	16.9	17.2
Cost-income ratio (%)	63.4	53.8	55.0	48.6	43.7
PAT/PPOP (%)	28.3	40.5	45.8	51.4	54.4
Shares outstanding (mn)	69.3	91.6	91.6	141.7	141.7

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	693	916	916	1,417	1,417
Reserves & surplus	9,147	13,468	17,963	31,240	36,514
Net worth	9,840	14,384	18,879	32,656	37,931
Borrowings	31,489	46,532	54,479	70,907	98,564
Other liabilities & prov.	1,726	1,884	2,065	2,271	2,499
Total liabilities & equity	43,056	62,800	75,423	105,835	138,994
Net loans	38,064	54,322	71,696	96,456	125,989
Investments	601	592	566	2,117	2,780
Cash, other balances	2,118	4,549	410	4,167	6,739
Interest earning assets	40,783	59,463	71,676	101,626	134,260
Fixed assets	38	45	54	65	78
Other assets	2,235	3,292	2,697	3,031	3,408
Total assets	43,056	62,800	75,423	105,835	138,994
BVPS (Rs)	142.0	157.0	206.1	230.5	267.7
Adj. BVPS (INR)	142.0	157.0	206.1	230.5	267.7
Gross loans	38,677	49,690	64,092	86,473	113,293
Total AUM	60,810	90,470	128,185	172,945	226,585
On balance sheet	36,390	49,690	64,092	86,473	113,293
Off balance sheet	24,420	40,780	64,092	86,473	113,293
Disbursements	46,410	58,670	77,765	100,231	128,609
Disbursements growth (%)	104.9	26.4	32.5	28.9	28.3
Loan growth (%)	55.3	42.7	32.0	34.5	30.6
AUM growth (%)	104.8	48.8	41.7	34.9	31.0
Borrowings growth (%)	74.7	47.8	17.1	30.2	39.0
Book value growth (%)	3.6	10.6	31.3	11.8	16.2

Asset quality and other metrics						
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E	
Asset quality						
GNPL - Stage 3	957	1,535	1,987	2,767	3,569	
NNPL - Stage 3	499	798	974	1,314	1,695	
GNPL ratio - Stage 3 (%)	2.5	3.1	3.1	3.2	3.2	
NNPL ratio - Stage 3 (%)	1.3	1.7	1.6	1.6	1.5	
ECL coverage - Stage 3 (%)	49.0	48.0	51.0	52.5	52.5	
ECL coverage - 1 & 2 (%)	1.1	0.9	1.2	1.4	1.7	
Gross slippage - Stage 3	0	0	0	0	0	
Gross slippage ratio (%)	0.0	0.0	0.0	0.0	0.0	
Write-off ratio (%)	0.3	2.0	1.8	1.6	1.5	
Total credit costs (%)	1.9	2.7	2.7	2.7	2.6	
NNPA to networth (%)	5.1	5.6	5.2	4.0	4.5	
Capital adequacy						
Total CAR (%)	20.2	20.8	21.1	27.6	24.5	
Tier-1 (%)	19.6	20.3	20.8	27.3	24.3	
Miscellaneous						
Total income growth (%)	119.9	66.3	41.7	40.8	35.0	
Opex growth (%)	94.6	41.2	44.8	24.5	21.3	
PPOP margin (%)	4.6	6.9	7.2	8.7	9.7	
Credit costs-to-PPOP (%)	40.4	39.4	38.3	30.8	26.7	
Loan-to-Assets (%)	88.4	86.5	95.1	91.1	90.6	
Yield on loans (%)	15.8	16.4	16.9	17.1	17.2	
Cost of funds (%)	11.8	11.4	11.1	11.0	10.8	
Spread (%)	3.9	5.1	5.8	6.1	6.4	

Source: Company, Emkay Research Note Credit cost; GNPL & NNPL is based on on-b/s loan book

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	49.7	21.1	13.9	9.8	7.6
P/B (x)	2.0	1.8	1.4	1.2	1.1
P/ABV (x)	2.0	1.8	1.4	1.2	1.1
P/PPOP (x)	14.1	8.5	6.4	5.0	4.1
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
Dupont-RoE split (%)					
NII/avg AUM	6.2	6.2	7.1	8.0	8.1
Other income	6.3	8.7	8.8	9.0	9.1
Securitization income	0.0	0.0	0.0	0.0	0.0
Opex	3.4	3.7	4.1	3.5	3.3
Employee expense	4.6	4.2	4.6	4.8	4.3
PPOP	4.6	6.9	7.2	8.7	9.7
Provisions	1.9	2.7	2.7	2.7	2.6
Tax expense	1.4	1.4	1.1	1.5	1.8
RoAUM (%)	1.3	2.8	3.3	4.5	5.3
Leverage ratio (x)	3.1	3.6	3.2	3.2	2.8
RoE (%)	4.1	9.9	10.6	14.3	14.9
Quarterly data					
Rs mn, Y/E Mar	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
NII	507	688	665	661	636
NIM(%)	14.6	13.4	14.8	14.8	16.9
PPOP	511	566	654	761	970
PAT	140	252	289	325	327
EPS (Rs)	2.03	3.06	3.17	3.56	3.57

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Nov-23	266	425	Buy	Avinash Singh
28-Oct-23	304	425	Buy	Avinash Singh
23-Oct-23	282	425	Buy	Avinash Singh

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests 2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 5, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3 during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of May 5, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the May 5, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

	········ y - ······· y - ··········				
Ratings	Expected Return within the next 12-18 months.				
BUY	>15% upside				
ADD	5-15% upside				
REDUCE	5% upside to 15% downside				
SELL	<15% downside				

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.